In this scenario, anti-IL-1 therapies proved to have therapeutic effect in inhibiting proinflammatory caspase-1, pathogenic element characteristic for CMS, and associated with aberrant inflammasome signaling, resulting in a new horizon for metabolic diseases treatment. This evidence concerns the gene IL1B and Other metabolic disease.